# Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies

> **NCT05164458** · PHASE1 · UNKNOWN · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 320 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** IBI 308 injection
- **DRUG:** IBI 389 Injection

## Key facts

- **NCT ID:** NCT05164458
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-22
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2023-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05164458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05164458, "Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05164458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*